StoryTest
Petrelintide Phase 2 ZUPREME-1 trial meets primary endpoint for weight loss
The ZUPREME-1 Phase 2 trial (n=493) of petrelintide for weight management met its primary endpoint. All five petrelintide doses showed significant weight loss at 28 weeks in people with obesity without type 2 diabetes.
- 493 participants across 11 countries enrolled in the trial
- All dose levels demonstrated clinically significant weight loss benefit
- Trial further validates the amylin pathway for obesity treatment